Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids in Gastric Cancer Malignant Ascites: a Phase I/II Clinical Study (IPIZA)

Next Previous
Trial Profile

Efficacy and Safety of Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids in Gastric Cancer Malignant Ascites: a Phase I/II Clinical Study (IPIZA)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Zoledronic acid (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Malignant ascites
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IPIZA

Most Recent Events

  • 19 Nov 2025 Planned End Date changed from 1 Feb 2025 to 1 Sep 2026.
  • 19 Nov 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Sep 2026.
  • 09 Jan 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top